Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases

Hoefert, Sebastian; Eufinger, H.

doi:10.1016/j.tripleo.2010.04.049

Cited by 97 publications

(58 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[55][56][57][58][59][60][61][62] In a limited cohort, Christodolou et al observed 5 cases of ONJ among 116 patients who had been receiving BPs from 2007 to 2008, of which 4 had received bevacizumab or sunitinib, [10] thus suggesting an increased risk of ONJ, which is derived from an association of BPs and innovative agents.…”

Section: Association Of Antingiogenic Drugs and Antiresorptive Agentsmentioning

confidence: 99%

“…[89] Besides initial reports of patients also treated with BPs, [10,55,56,58,62,90] sunitinib appeared as the only agent administered in some RCC patients suffering of ONJ [59][60][61] Furthermore, sunitinib was associated to BPs in numerous ONJ cases in RCC population, [67] with an incidence higher than expected when a denominator was reported. [13,57,69] However, Smidt-Hansen reported the possibility of decreasing the ONJ risk after adopting preventive measures (as well as recommended in general BP-treated population).…”

Section: Sunitinibmentioning

confidence: 99%

See 1 more Smart Citation

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

Fusco

Santini

Armento

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Introduction: Osteonecrosis of the jaw (ONJ) is a clinically important, potentially painful and debilitating condition, which can affect the quality of life of cancer patients. Since 2003, ONJ appeared as a Bisphosphonate(BP)-related class effect, and the term Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) was widespread. Areas Covered: Under discussion in this review is the fact that ONJ cases have been reported after treatment including antiangiogenic agents and other “targeted therapy”, with and without BPs. Consequently, the comprehensive term Medication-Related Osteonecrosis of the Jaw (MRONJ) has been introduced. The clinical aspects and the prognosis of ONJ associated with these new drugs are still less reported, but basing on their pharmacodynamics, they could be different from the well-known BRONJ. Accordingly, recommendations largely in use for BRONJ should be extended to these new forms, but critically applied and with respect to the individual risk assessment. Expert Opinion: There is a high risk of underdiagnoses for ONJ due to a lack of awareness, and too much restrictive or incomplete diagnostic criteria; at the same time, with regard to ONJ associated to the new non –antiresorptive agents, described here, we observe the strong need to improve the defining of any distinguished feature in their diagnosis, prevention and therapy

show abstract

Section: Association Of Antingiogenic Drugs and Antiresorptive Agentsmentioning

confidence: 99%

Section: Sunitinibmentioning

confidence: 99%

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

Fusco

Santini

Armento

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…In the present study, 2 of the patients were treated with corticosteroid for rheumatoid arthritis another 3 had diabetes mellitus. Some recent case reports noted that anti-RANKL (receptor activator of nuclear factor-kappa B ligand) antibody, denosumab, and the molecularlytargeted anticancer drug sunitinib caused osteonecrosis of the jaw with different mechanisms of action 8,14) . For this reason, recently this disease has been called "DIONJ; drug induced osteonecrosis of the jaw" instead of BRONJ.…”

Section: Patients Treated With Bp For Osteoporosismentioning

confidence: 99%

Bisphosphonate-related Osteonecrosis of Jaw (BRONJ) in Japanese Population: A Case Series of 13 Patients at Our Clinic

Nomura

Shibahara

Uchiyama

et al. 2013

Bull. Tokyo Dent. Coll.

View full text Add to dashboard Cite

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) affects quality of life and is an important problem for dentists. A Japanese position paper on BRONJ was published in 2010. The purpose of this study was to review clinical data on the treatment of BRONJ obtained at the Clinic of Oral and Maxillofacial Surgery, Tokyo Dental College, Chiba Hospital to further our understanding of this disease. A total of 13 patients (6 men and 7 women) were included. All the patients included in this study had received Bisphosphonate (BP) therapy and had BRONJ. Five of them (38.5%) had received oral BP therapy for osteoporosis, while the remaining 8 (61.5%) had received parenteral BP therapy for bone metastases from breast or prostate cancer. Osteoporosis patients were treated with risedronate or alendronate. Breast or prostate cancer patients were treated with zoledronate. Two patients with rheumatoid arthritis were treated with corticosteroid. Three patients had diabetes mellitus. Eleven patients were treated with antibiotics, while 5 underwent surgical treatment. Discontinuation of BP was recorded in 7 patients during dental treatment. Sequestration was observed in 6 patients during an 11-month follow-up. Eventually, healing and improvement of the oral mucosa were observed in 3 patients. The current standard treatment for BRONJ does not always provide good results. It is necessary to accumulate further clinical data to establish more effective treatment strategies for BRONJ.

show abstract

“…In recent years, some cases of ONJ have been reported during treatment with bevacizumab 14,15 and sunitinib. 16 whereby it is possible that the potent antiangiogenic activity of VEGF-targeting agents may inhibit bone remodeling and promote ONJ development. Additionally, it is possible that these drugs may compromise the integrity of the bone and mucosal blood supply.…”

Section: Stagementioning

confidence: 99%

Multifocal brown tumor of the maxilla and mandible in primary hyperparathyroidism – diagnostic challenges and literature review

Gogolewski¹,

Jędrusik-Pawłowska²,

Drozdzowska³

2017

Dent. Med. Probl.

View full text Add to dashboard Cite

Osteonecrosis of the jaw (ONJ) is a rare treatment-related side effect of anti-resorptive drugs whose risk is increased by concomitant local and systemic factors. The number of cases of medication-related ONJ is constantly increasing as a result of the rising tide of molecular-targeted and immunological drugs used in cancer treatment. Denosumab-related ONJ presents peculiar pathophysiological, histopathological, clinical, and therapeutic features compared to that induced by bisphosphonates-related ONJ.This study aimed to compare ONJ induced by denosumab to that caused by bisphosphonates. We have reviewed the literature of the last 5 years on denosumab-related ONJ, focusing on reviews and metaanalyses.The physiopathology of ONJ is unclear. Denosumab acts on receptor activator of nuclear factor kappa-B ligand (RANKL) to inhibit the formation and activity of osteoclasts. The reduction of bone turnover seems to play an important role. Dentists and oral surgeons in the coming years will see an increasing number of patients who are receiving treatment potentially toxic to bone, but also require good dental care. Early recognition of ONJ is essential in the patient's treatment with denosumab, therefore a close collaboration between the dentist and oncologist is fundamental.

show abstract

Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases

Cited by 97 publications

References 16 publications

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

Bisphosphonate-related Osteonecrosis of Jaw (BRONJ) in Japanese Population: A Case Series of 13 Patients at Our Clinic

Multifocal brown tumor of the maxilla and mandible in primary hyperparathyroidism – diagnostic challenges and literature review

Contact Info

Product

Resources

About